Movement Alert|SKB BIO rises 3.59% in Regular Trading, clinical and filing progress in core drug offers support

Market Focus11-04

On November 4, SKB BIO rose 3.59% in Regular Trading, with shares trading at HK$414.4 and turnover of HK$73.84 million.

The move was accompanied by continued positive progress around its core product sacituzumab tirumotecan, which has recently provided support to sentiment.

Background details show the company recently presented three Phase III studies for sac-TMT at ESMO, including lung cancer data indicating progression-free survival and overall survival benefit. In addition, its new indication application for sac-TMT combined with pembrolizumab as first-line treatment for PD-L1-negative non-squamous NSCLC has been accepted for review in China. After these updates, several brokers maintained positive ratings, with target prices ranging from HK$520 to HK$678.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment